The estimated Net Worth of Janet Dorling is at least $201 Tausend dollars as of 12 February 2024. Janet Dorling owns over 6,000 units of Cymabay Therapeutics Inc stock worth over $194,880 and over the last 6 years Janet sold CBAY stock worth over $6,366.
Janet has made over 7 trades of the Cymabay Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Janet exercised 6,000 units of CBAY stock worth $27,780 on 12 February 2024.
The largest trade Janet's ever made was exercising 7,000 units of Cymabay Therapeutics Inc stock on 10 November 2023 worth over $32,410. On average, Janet trades about 1,822 units every 137 days since 2018. As of 12 February 2024 Janet still owns at least 6,000 units of Cymabay Therapeutics Inc stock.
You can see the complete history of Janet Dorling stock trades at the bottom of the page.
Janet's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7601 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster und Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.
cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.
Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include: